Skip to main content
TipRanks
Go Ultimate75% OFF

Nuvation Bio (NUVB) Revenue by Type

929 Followers

Revenue by Type

Nuvation Bio reported revenue by type of $31.69M in Q2 2026, down 61.9% from Q1 2026 and up 555.6% year over year. The highest value was $83.23M in Q1 2026.

Breaks down revenue into sources such as product sales, licensing, collaboration and milestone payments, and grants, highlighting whether income is recurring or one-time. For clinical-stage Nuvation Bio, which likely has limited commercial sales, this reveals reliance on partnerships and milestone receipts to fund R&D, the timing risks to cash flow and runway, and how close the company is to generating steady product revenue.

$0.00$20.00M$40.00M$60.00M$80.00MMar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Product revenue has moved from zero to a meaningful ramp driven by Iptrozy's growing first‑line share and sequential unit growth, but the recent quarter’s surge was predominantly an Eisai upfront in collaboration revenue—underscoring lumpiness and milestone dependence. Sustainable, non‑volatile net revenue hinges on expanding new patient starts and testing adoption and maintaining first‑line penetration while GTN normalizes and hefty operating spend continues; management’s cash cushion lowers financing risk, though milestone timing keeps near‑term quarters volatile.

NUVB Revenue by Type

PeriodProductCollaboration & License AgreementsTotal
Q2 2026Jun 30, 2026$23.19M$8.49M$31.69M
Q1 2026Mar 31, 2026$18.51M$64.72M$83.23M
Q4 2025Dec 31, 2025$15.70M$26.16M$41.87M
Q3 2025Sep 30, 2025$7.72M$5.40M$13.12M
Q2 2025Jun 30, 2025$1.24M$3.60M$4.83M
Q1 2025Mar 31, 2025$0.00$3.08M$3.08M
Q4 2024Dec 31, 2024$0.00$5.71M$5.71M
Q3 2024Sep 30, 2024$0.00$727.00K$727.00K
Q2 2024Jun 30, 2024$0.00$1.44M$1.44M
Q1 2024Mar 31, 2024$0.00$0.00$0.00

Related KPIs